SNDX
Syndax Pharmaceuticals Inc · Healthcare · Market cap $843.2M
Insiders sold $114K net in the last 90 days ·1 seller, 0 buyers· 1 of 1 sale under Rule 10b5-1 plans· latest Form 4 filed Oct 30, 2026
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$2.9M
reported sales (SEC code S)
Unique Insiders
4
in the rolling window
Latest filing
Oct 30, 2026
Podlesak Dennis
Syndax Pharmaceuticals Inc (SNDX) has 17 SEC Form 4 filings (28 transaction rows) in the rolling window, disclosed by 4 distinct insiders. Most recent filing: Oct 30, 2026.
Inside the rolling window, 4 insiders at Syndax Pharmaceuticals Inc reported no open-market purchases and 10 open-market sales totaling $2.9M. The most active filer is Chief Executive Officer Metzger Michael A with 4 filings. Insiders have net sold $2.2M over the trailing 6 months. The most recent open-market filing is a sale of 8,000 shares by Director Podlesak Dennis, dated Oct 29, 2026, worth $114K.
- Industry:Biotechnology
- CEO:Michael A. Metzger
- Employees:298
- HQ:New York City, NY, US
- IPO:2016-03-02
| Source | |||||||
|---|---|---|---|---|---|---|---|
Podlesak DennisFirst filing | Director | Sale | 8,000 | $114K | Oct 30 | -31.4% | SEC ↗ |
| Chief Executive Officer | Sale | 32,375 | $785K | Jul 9 | -62.3% | SEC ↗ | |
Botwood Nicholas A.J.First filing | Head of R&D, CMO | Sale | 34,280 | $617K | Jun 12 | -48.7% | SEC ↗ |
Botwood Nicholas A.J.First filing | Head of R&D, CMO | Sale | 31,235 | $567K | Jun 12 | -48.7% | SEC ↗ |
Metzger Michael AFirst in 4 months | Chief Executive Officer | Sale | 6,847 | $130K | Jun 2 | -49.0% | SEC ↗ |
Goldan Keith A.First in 4 months | Chief Financial Officer | Sale | 1,177 | $22K | Jun 2 | -49.0% | SEC ↗ |
| Chief Financial Officer | Sale | 3,410 | $72K | Feb 10 | -56.1% | SEC ↗ | |
| Chief Executive Officer | Sale | 17,159 | $361K | Feb 10 | -56.1% | SEC ↗ | |
Goldan Keith A.First filing | Chief Financial Officer | Sale | 2,082 | $43K | Feb 6 | -55.4% | SEC ↗ |
Metzger Michael AFirst filing | Chief Executive Officer | Sale | 7,412 | $153K | Feb 6 | -55.4% | SEC ↗ |
Frequently asked questions
How many SEC Form 4 insider filings does SNDX have?
Syndax Pharmaceuticals Inc (SNDX) has 17 SEC Form 4 filings (28 transaction rows) in the rolling 365-day window, disclosed by 4 distinct insiders. Most recent filing: Oct 30, 2026.
When was the most recent SEC Form 4 filing for SNDX?
The most recent Form 4 filing for SNDX on Tracefour is dated Oct 30, 2026.
Who is the most active insider at SNDX?
The most active SEC Form 4 filer at SNDX in the rolling window is Chief Executive Officer Metzger Michael A, with 4 filings.
What is the net insider flow at SNDX over the last 6 months?
Over the trailing 180 days, insiders at SNDX have net sold $2.2M based on SEC Form 4 disclosures.
What is the total insider buy and sell value at SNDX in the current window?
Inside the rolling window, insiders at SNDX bought $0 and sold $2.9M based on SEC Form 4 filings.
Can I get alerts for SNDX insider trading?
Yes. Tracefour sends a free email when a new SEC Form 4 purchase or sale is filed at Syndax Pharmaceuticals Inc (SNDX). Alerts are set per company from the page itself, there is no paid tier, and each email links to the original filing on SEC EDGAR.
Related companies
Syndax Pharmaceuticals Inc is in the Healthcare sector.